NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Total Current Assets
All assets expected to be converted to cash or used up within one year.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets broadly unchanged from a year ago
Total current assets stood at $7.36M at the end of Q1 FY2026, up 1.4% from a year earlier and down 17.2% from the prior quarter. Over 3 fiscal years it compounded at -29.9% a year.
Context
- Total current assets amounted to 61.8% of total assets at the end of Q1 FY2026, down 33.8 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +1.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 8.89M USD
- Year-over-year change
- +169.3%
- 4-year CAGR
- -27.8%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.89M | +169.3% |
| FY2024 | 2024-12-31 | 3.3M | -52.0% |
| FY2023 | 2023-12-31 | 6.88M | -73.3% |
| FY2022 | 2022-12-31 | 25.8M | -21.1% |
| FY2021 | 2021-12-31 | 32.71M | — |
Total Current Assets vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 total current assets of $7.36M is the 8th highest of the 9 companies compared; the peer median is $40.71M.
- Its year-over-year change of +1.4% is the 7th highest of 9, against a peer median of +22.2%.
- Total current assets amounts to 61.8% of total assets for NRXP, versus a peer median of 95.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $139.04M | -18.0% | -27.7% | 42.6% | |
| Mar 2026 | $126.33M | +5.1% | -33.5% | 96.1% | |
| Mar 2026 | $62.28M | +284.0% | -26.7% | 98.7% | |
| Mar 2026 | $55.03M | +80.0% | -14.6% | 98.0% | |
| Mar 2026 | $26.39M | +65.7% | -21.7% | 85.5% | |
| Jun 2026 | $22.89M | -71.5% | -25.2% | 94.8% | |
| Mar 2026 | $20.9M | +17.4% | -14.2% | 95.5% | |
| Mar 2026 | $7.36M | +1.4% | -29.9% | 61.8% | |
| Mar 2026 | $5.91M | +27.0% | +23.1% | 29.9% | |
| Peer median (excluding NRXP) | $40.71M | +22.2% | -23.5% | 95.1% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.